Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 823,400 | 513,900 | 188,700 | 310,600 | 1,046,900 |
| Depreciation Amortization | 107,200 | 74,600 | 49,000 | 24,500 | 89,300 |
| Income taxes - deferred | -49,400 | -37,800 | -39,200 | 3,600 | 12,100 |
| Accounts receivable | 41,900 | -9,200 | 21,500 | -4,200 | -88,000 |
| Other Working Capital | -228,300 | -266,800 | -212,200 | -174,700 | 3,200 |
| Other Operating Activity | 359,500 | 379,800 | 430,600 | 47,300 | 119,400 |
| Operating Cash Flow | $1,054,300 | $654,500 | $438,400 | $207,100 | $1,182,900 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | -21,900 | N/A | N/A |
| PPE Investments | -407,000 | -293,800 | -190,500 | -82,200 | -254,400 |
| Net Acquisitions | -10,000 | -10,000 | -10,000 | N/A | -135,200 |
| Purchase Of Investment | -851,700 | -506,300 | -387,700 | -262,900 | -568,100 |
| Sale Of Investment | 777,000 | 570,500 | 467,200 | 228,000 | 409,900 |
| Purchase Sale Intangibles | -300 | N/A | N/A | N/A | -24,000 |
| Other Investing Activity | -39,400 | -31,600 | -2,000 | -17,600 | -48,000 |
| Investing Cash Flow | $-531,100 | $-271,200 | $-144,900 | $-134,700 | $-595,800 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 16,200 | 12,300 | 10,600 | 7,900 | 18,900 |
| Debt Repayment | -17,000 | -14,000 | -11,800 | -8,200 | -28,900 |
| Common Stock Issued | 140,500 | 103,500 | 67,300 | 29,100 | 160,500 |
| Common Stock Repurchased | -625,400 | -625,200 | -623,800 | -614,800 | -263,300 |
| Other Financing Activity | -1,200 | -4,900 | -4,600 | -400 | -2,800 |
| Financing Cash Flow | $-486,900 | $-528,300 | $-562,300 | $-586,400 | $-115,600 |
| Exchange Rate Effect | -20,500 | -9,900 | -6,600 | -2,100 | -3,000 |
| Beginning Cash Position | 1,184,400 | 1,184,400 | 1,184,400 | 1,184,400 | 715,900 |
| End Cash Position | 1,200,200 | 1,029,500 | 909,000 | 668,300 | 1,184,400 |
| Net Cash Flow | $15,800 | $-154,900 | $-275,400 | $-516,100 | $468,500 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,054,300 | 654,500 | 438,400 | 207,100 | 1,182,900 |
| Capital Expenditure | -407,000 | -293,800 | -190,500 | -82,200 | -254,400 |
| Free Cash Flow | 647,300 | 360,700 | 247,900 | 124,900 | 928,500 |